Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targetting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells.
Ziv-aflibercept (Zaltrap®) is a type of tyrosine kinase inhibitor (TKI) that prevents the growth of cancer cells by blocking the formation of new blood vessels in tumours. It is similar to already approved medications such as Sunitinib (Sutent®), Pazopanib (Votrient®), and Axitinib (Inlyta®).
This study will investigate the safety and effectiveness of Pembrolizumab in combination with Ziv-aflibercept.
Different doses of each drug will be used to determine the optimal dosage.
- All subtypes eligible
- Advanced kidney cancer that cannot be removed by surgery
- At least 1 prior treatment with a TKI therapy
Additional eligibility criteria will apply. Please speak to your doctor.Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreBC Cancer - Vancouver Site||Principal InvestigatorN/A||LocationVancouver, BC||Trial StatusActive, Not Recruiting|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorDr Philippe L. Bédard||LocationToronto, ON||Trial StatusSuspended|